Next-Generation Sequencing in a Cohort of Asian Indian Patients with the Duchenne Muscular Dystrophy Phenotype: Diagnostic Yield and Mutation Spectrum

Abstract

Multiplex ligation-dependent probe amplification (MLPA) detects exonic deletions and duplications in the DMD gene in around 65 to 70% of patients with the Duchenne muscular dystrophy (DMD) phenotype. This study looks at the diagnostic yield of next-generation sequencing (NGS) and the mutation spectrum in an Asian Indian cohort of MLPA-negative cases with the DMD phenotype. NGS-based sequencing of DMD gene was done in 28 MLPA-negative cases (25 male probands with the DMD phenotype and 3 obligate carrier mothers of deceased affected male patients) and disease-causing variants were identified in 19 (67.9%) of these cases. Further molecular testing in four of the remaining nine cases revealed gene variants associated with limb girdle muscular dystrophies. Thus, NGS-based multigene panel testing for muscular dystrophy-associated genes or clinical exome sequencing rather than targeted DMD gene sequencing appears to be a more cost-effective testing modality with better diagnostic yield, for MLPA-negative patients with the DMD phenotype.

Keywords

Duchenne muscular dystrophy - next-generation sequencing - DMD gene sequence variants

• References

• 1 Lim BC, Lee S, Shin JY. et al. Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. J Med Genet 2011; 48 (11) 731-736
• 2 Swaminathan B, Shubha GN, Shubha D. et al. Duchenne muscular dystrophy: a clinical, histopathological and genetic study at a neurology tertiary care center in Southern India. Neurol India 2009; 57 (06) 734-738
• 3 Tallapaka K, Ranganath P, Ramachandran A. et al. Molecular and histopathological characterization of patients presenting with the Duchenne muscular dystrophy phenotype in a tertiary care center in southern India. Indian Pediatr 2019; 56 (07) 556-559
• 4 Freed D, Aldana R, Weber JA, Edwards JS. The sentieon genomics tools — a fast and accurate solution to variant calling from next-generation sequence data. bioRxiv 2017;
• 5 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 6 Roberts RG, Bobrow M, Bentley DR. Point mutations in the dystrophin gene. Proc Natl Acad Sci U S A 1992; 89 (06) 2331-2335
• 7 Santos R, Gonçalves A, Oliveira J. et al. New variants, challenges and pitfalls in DMD genotyping: implications in diagnosis, prognosis and therapy. J Hum Genet 2014; 59 (08) 454-464
• 8 Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 2016; 53 (03) 145-151
• 9 Wang Y, Yang Y, Liu J. et al. Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. Mol Genet Genomics 2014; 289 (05) 1013-1021
• 10 Okubo M, Minami N, Goto K. et al. Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations. J Hum Genet 2016; 61 (06) 483-489
• 11 Plagnol V, Curtis J, Epstein M. et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics 2012; 28 (21) 2747-2754
• 12 Bovolenta M, Scotton C, Falzarano MS, Gualandi F, Ferlini A. Rapid, comprehensive analysis of the dystrophin transcript by a custom micro-fluidic exome array. Hum Mutat 2012; 33 (03) 572-581
• 13 Singh B, Mandal K, Lallar M. et al. Next generation sequencing in diagnosis of mlpa negative cases presenting as Duchenne/Becker muscular dystrophies. Indian J Pediatr 2018; 85 (04) 309-310
• 14 Aravind S, Ashley B, Mannan A. et al. Targeted sequencing of the DMD locus: A comprehensive diagnostic tool for all mutations. Indian J Med Res 2019; 150 (03) 282-289
• 15 Kohli S, Saxena R, Thomas E. et al. Mutation Spectrum of Dystrophinopathies in India: Implications for Therapy. Indian J Pediatr 2020; (e-pub ahead of print)
• 16 McDonald CM, Campbell C, Torricelli RE. et al; Clinical Evaluator Training Group; ACT DMD Study Group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390 (10101): 1489-1498
• 17 Haas M, Vlcek V, Balabanov P. et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord 2015; 25 (01) 5-13
• 18 Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015; 6: 6244